These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8582386)

  • 21. Circadian variation in defibrillation energy requirements.
    Venditti FJ; John RM; Hull M; Tofler GH; Shahian DM; Martin DT
    Circulation; 1996 Oct; 94(7):1607-12. PubMed ID: 8840851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Implantable defibrillator using epicardial and endocardial leads. Results of 36 implantations].
    Sadoul N; Poujois JN; Pinelli G; Villemot JP; de Chillou C; Kanj H; Reeb T; Dodinot B; Aliot E
    Arch Mal Coeur Vaiss; 1993 Nov; 86(11):1567-72. PubMed ID: 8010856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
    Klein HU; Goldenberg I; Moss AJ
    Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of ventricular tachyarrhythmias following improvement of left ventricular ejection fraction in patients with implantable cardiac defibrillators implanted for primary prevention of sudden cardiac death.
    Pillarisetti J; Gopinathannair R; Haney MJ; Abazid B; Rawasia W; Reddy MY; Adabala N; Bommana S; Emert M; Lakkireddy D
    J Interv Card Electrophysiol; 2017 Apr; 48(3):283-289. PubMed ID: 28150095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylactic catheter ablation for the prevention of defibrillator therapy.
    Reddy VY; Reynolds MR; Neuzil P; Richardson AW; Taborsky M; Jongnarangsin K; Kralovec S; Sediva L; Ruskin JN; Josephson ME
    N Engl J Med; 2007 Dec; 357(26):2657-65. PubMed ID: 18160685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
    Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M
    Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
    Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Experience with the use of an implantable automatic cardioverter defibrillator].
    Dórticos F; Zayas R; Dorantes M; Tain J; Bueno J; Carballido J; Sainz H
    Arch Inst Cardiol Mex; 1990; 60(5):499-502. PubMed ID: 2091555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience with implantable cardioverter defibrillator therapy in elderly patients.
    Geelen P; Lorga Filho A; Primo J; Wellens F; Brugada P
    Eur Heart J; 1997 Aug; 18(8):1339-42. PubMed ID: 9458428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Left Ventricular Dilatation Increases the Risk of Ventricular Arrhythmias in Patients With Reduced Systolic Function.
    Aleong RG; Mulvahill MJ; Halder I; Carlson NE; Singh M; Bloom HL; Dudley SC; Ellinor PT; Shalaby A; Weiss R; Gutmann R; Sauer WH; Narayanan K; Chugh SS; Saba S; London B
    J Am Heart Assoc; 2015 Jul; 4(8):e001566. PubMed ID: 26231842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Torsades de pointes and aborted sudden death after implantation of a cardioverter defibrillator.
    de Meester A; Djian D; Jacques JM; Luwaert R; Chaudron JM
    Acta Cardiol; 1994; 49(6):543-8. PubMed ID: 7771164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sudden cardiac death and implantable cardioverter-defibrillators.
    Turakhia MP
    Am Fam Physician; 2010 Dec; 82(11):1357-66. PubMed ID: 21121520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implantable defibrillators for high-risk patients with heart failure who are awaiting cardiac transplantation.
    Saxon LA; Wiener I; DeLurgio DB; Natterson PD; Laks H; Drinkwater DC; Stevenson WG
    Am Heart J; 1995 Sep; 130(3 Pt 1):501-6. PubMed ID: 7661067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
    Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
    Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience.
    Conte G; Sieira J; Ciconte G; de Asmundis C; Chierchia GB; Baltogiannis G; Di Giovanni G; La Meir M; Wellens F; Czapla J; Wauters K; Levinstein M; Saitoh Y; Irfan G; Julià J; Pappaert G; Brugada P
    J Am Coll Cardiol; 2015 Mar; 65(9):879-88. PubMed ID: 25744005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
    Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unexpected shift in circadian and septadian variation of sudden cardiac arrest: the Oregon Sudden Unexpected Death Study.
    Ni YM; Rusinaru C; Reinier K; Uy-Evanado A; Chugh H; Stecker EC; Jui J; Chugh SS
    Heart Rhythm; 2019 Mar; 16(3):411-415. PubMed ID: 30193852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
    Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB
    J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time to first shock and clinical outcome in patients receiving an automatic implantable cardioverter-defibrillator.
    Myerburg RJ; Luceri RM; Thurer R; Cooper DK; Zaman L; Interian A; Fernandez P; Cox M; Glicksman F; Castellanos A
    J Am Coll Cardiol; 1989 Aug; 14(2):508-14. PubMed ID: 2754136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.